ArticleActa dermato-venereologica2025

Real-world Drug Survival of Biosimilar SB5 vs GP2017 Following a Mandatory Non-medical Switch from Adalimumab Originator for Psoriasis: A Nationwide Cohort Study.

Johan Sieborg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.